ALNY241018C280000
- 7.06
- +0.13+1.88%
Alnylam Pharmaceuticals Newsroom
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $307
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Announces Target Price $307
Looking Into Alnylam Pharmaceuticals's Recent Short Interest
Alnylam to Webcast TTR Investor Day
Alnylam Pharma Confident in ATTR-CM Treatment's Market Potential, Cautious on Regulatory Risks, RBC Says
Alnylam Pharmaceuticals Price Target Maintained With a $300.00/Share by RBC Capital
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating
BofA Securities analyst Tazeen Ahmad maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 53.0% and a total average return of 4.
TD Cowen Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $282
TD Cowen analyst Ritu Baral maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $282.According to TipRanks data, the analyst has a success rate of 47.6%
TD Cowen Sticks to Their Buy Rating for Alnylam Pharma (ALNY)
Is Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Trading At A 49% Discount?
The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 10 Years
Cantor Fitzgerald Reiterates Neutral on Alnylam Pharmaceuticals, Maintains $220 Price Target
Alnylam Pharmaceuticals, Inc. (ALNY): Do Hedge Funds Recommend This Biotech Stock Now?
Evercore Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $260
Evercore analyst Liisa Bayko maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $260.According to TipRanks data, the analyst has a success rate of 45.7%
RBC Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $300
RBC Capital analyst Luca Issi maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $300.According to TipRanks data, the analyst has a success rate of 22.2%
BofA Securities Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $307
BofA Securities analyst Tazeen Ahmad maintains $Alnylam Pharmaceuticals(ALNY.US)$ with a buy rating, and maintains the target price at $307.According to TipRanks data, the analyst has a success rate
A Quick Look at Today's Ratings for Alnylam Pharmaceuticals(ALNY.US), With a Forecast Between $275 to $400
On Sep 04, major Wall Street analysts update their ratings for $Alnylam Pharmaceuticals(ALNY.US)$, with price targets ranging from $275 to $400.BofA Securities analyst Tazeen Ahmad maintains with a
B of A Securities Maintains Buy on Alnylam Pharmaceuticals, Raises Price Target to $307
ProofPilot Bolsters Advisory Board With Appointment of Michelle Everill